Program
tovorafenib
Also written as “Tovorafenib”, “MLN2480” and “TAK-580”.
Its studies are mostly in Melanoma, led by 3 companies.
Furthest: phase 3, since Sep 16, 20228 company-led studies, 3 open or runningNext primary completion: May 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Day One Biopharmaceuticals | 42 open or running | phase 3since Sep 16, 2022 | Feb 3, 2021 | May 31, 2027phase 2 · NCT04775485 |
| Takeda | 30 open or running | phase 1since Aug 26, 2011 | Aug 26, 2011 | none ahead |
| Ipsen | 11 open or running | phase 1since Feb 17, 2026 | Feb 17, 2026 | Jul 31, 2030phase 1 · NCT07441707 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2011First study: phase 1 study in MelanomaNew to TakedaTakeda · NCT01425008 · 149 enrolled · United States, United Kingdom
- Dec 23, 2014Phase 1 study in Advanced Nonhematologic MalignanciesTakeda · NCT02327169 · 81 enrolled · United States, France, Spain and more
- Mar 25, 2016Phase 1 study in MelanomaTakeda · NCT02723006 · 22 enrolled · United States
- Feb 3, 2021Day One Biopharmaceuticals's first study: phase 2 study in Low-grade GliomaNew to Day One BiopharmaceuticalsDay One Biopharmaceuticals · NCT04775485 · 141 planned · United States, Australia, Canada and more
- Jun 23, 2021Phase 2 study in MelanomaDay One Biopharmaceuticals · NCT04985604 · 23 enrolled · United States, Australia, Belgium and more
- Sep 16, 2022Phase 3 study in Noonan Syndrome 5Day One Biopharmaceuticals · NCT05566795 · 418 enrolled · United States, Australia, Austria and more
- Jul 3, 2025Phase 1 study in MelanomaDay One Biopharmaceuticals · NCT07121829 · 44 enrolled · United States, Canada
- Feb 17, 2026Ipsen's first study: phase 1 study in Low-grade GliomaNew to IpsenIpsen · NCT07441707 · 6 enrolled · Japan
Ahead
- May 31, 2027Primary completion: phase 2 study in Low-grade GliomaDay One Biopharmaceuticals · NCT04775485
- Jun 2027Primary completion: phase 3 study in Noonan Syndrome 5Day One Biopharmaceuticals · NCT05566795
- Jul 31, 2030Primary completion: phase 1 study in Low-grade GliomaIpsen · NCT07441707
TargetBeta
“RAF serine/threonine protein kinase inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| belvarafenibrule | Hanmi Pharmaceutical | phase 2 | 6 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07441707Low-grade Glioma · Japan | 1 | Active, not recruiting | Ipsen | Jul 31, 2030 | 6 |
| NCT07121829Melanoma · United States, Canada | 1 | Terminated | Day One Biopharmaceuticals | Dec 18, 2024 | 44 |
| NCT05566795Noonan Syndrome 5 · United States, Australia, Austria and more | 3 | Active, not recruiting | Day One Biopharmaceuticals | Jun 2027 | 418 |
| NCT04985604Melanoma · United States, Australia, Belgium and more | 2 | Terminated | Day One Biopharmaceuticals | Jul 8, 2024 | 23 |
| NCT04775485Low-grade Glioma · United States, Australia, Canada and more | 2 | Recruiting | Day One Biopharmaceuticals | May 31, 2027 | 141 |
| NCT02723006Melanoma · United States | 1 | Terminated | Takeda | May 11, 2018 | 22 |
| NCT02327169Advanced Nonhematologic Malignancies · United States, France, Spain and more | 1 | Completed | Takeda | Jul 2, 2018 | 81 |
| NCT01425008Melanoma · United States, United Kingdom | 1 | Completed | Takeda | Apr 11, 2017 | 149 |
How it is read
Names in the registry
- “Tovorafenib”, 5 entries
- “MLN2480”, 2 entries
- “TAK-580”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.